These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 35993192)

  • 1. Insights into mechanisms of graft-versus-host disease through humanised mouse models.
    Elhage A; Sligar C; Cuthbertson P; Watson D; Sluyter R
    Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35993192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.
    Cuthbertson P; Button A; Sligar C; Elhage A; Vine KL; Watson D; Sluyter R
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model.
    Cuthbertson P; Geraghty NJ; Adhikary SR; Casolin S; Watson D; Sluyter R
    Clin Sci (Lond); 2021 Feb; 135(3):495-513. PubMed ID: 33463682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model.
    Ono R; Watanabe T; Kawakami E; Iwasaki M; Tomizawa-Murasawa M; Matsuda M; Najima Y; Takagi S; Fujiki S; Sato R; Mochizuki Y; Yoshida H; Sato K; Yabe H; Kato S; Saito Y; Taniguchi S; Shultz LD; Ohara O; Amagai M; Koseki H; Ishikawa F
    EBioMedicine; 2019 Mar; 41():584-596. PubMed ID: 30772305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased P2X7 expression in the gastrointestinal tract and skin in a humanised mouse model of graft-versus-host disease.
    Cuthbertson P; Adhikary SR; Geraghty NJ; Guy TV; Hadjiashrafi A; Fuller SJ; Ly D; Watson D; Sluyter R
    Clin Sci (Lond); 2020 Jan; 134(2):207-223. PubMed ID: 31934722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice.
    Adhikary SR; Geraghty NJ; Cuthbertson P; Sluyter R; Watson D
    Purinergic Signal; 2019 Jun; 15(2):177-192. PubMed ID: 31001750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased splenic human CD4
    Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
    Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
    Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
    Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
    Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
    J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The A
    Geraghty NJ; Adhikary SR; Watson D; Sluyter R
    Int Immunopharmacol; 2019 Jul; 72():479-486. PubMed ID: 31051404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
    Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
    Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early myeloid-derived suppressor cells (HLA-DR
    Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
    Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
    Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
    Pang Y; Holtzman NG
    Best Pract Res Clin Haematol; 2023 Jun; 36(2):101475. PubMed ID: 37353287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
    Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
    Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling Human Graft-Versus-Host Disease in Immunocompromised Mice.
    Norelli M; Camisa B; Bondanza A
    Methods Mol Biol; 2016; 1393():127-32. PubMed ID: 27033222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.
    King MA; Covassin L; Brehm MA; Racki W; Pearson T; Leif J; Laning J; Fodor W; Foreman O; Burzenski L; Chase TH; Gott B; Rossini AA; Bortell R; Shultz LD; Greiner DL
    Clin Exp Immunol; 2009 Jul; 157(1):104-18. PubMed ID: 19659776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
    Burger DR; Parker Y; Guinta K; Lindner D
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.